{"name":"Neos Therapeutics","slug":"neos","ticker":"NEOS","exchange":"NASDAQ","domain":"neostx.com","description":"Neos Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of innovative CNS and ADHD treatments. The company's top drugs include Adzenys ER and Cotempla. Neos Therapeutics is a relatively small player in the CNS/pharma market.","hq":"Grand Prairie, TX","founded":0,"employees":"","ceo":"Jerry McLaughlin","sector":"Specialty Pharma — CNS / ADHD","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":64649000,"revenueGrowth":284.1,"grossMargin":0,"rdSpend":8582000,"netIncome":-16902000,"cash":90873000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Adzenys ER patent cliff ($100M at risk)","drug":"Adzenys ER","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Cotempla patent cliff ($50M at risk)","drug":"Cotempla","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NT0102","genericName":"NT0102","slug":"nt0102","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"phase_3"}]}],"pipeline":[{"name":"NT0102","genericName":"NT0102","slug":"nt0102","phase":"phase_3","mechanism":"NT0102 is a prodrug formulation of methylphenidate designed to provide extended-release delivery with reduced abuse potential.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Neos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Neos Therapeutics reported its Q4 and full year 2023 financial results, with revenue of $24.4 million and a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Neos Therapeutics Announces Agreement with Sandoz to Develop and Commercialize Adzenys ER","summary":"Neos Therapeutics announced an agreement with Sandoz to develop and commercialize Adzenys ER, a long-acting stimulant for ADHD.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNelBtRGk5dFZ0WGl2S3pEVmwyVk1vRnFvYmFMcmJfTnBLSUlNRHNOV3VtUFNScGdrci1xVjhjY09DMGc1YmNodWxrN3pOUHhFeGQtLWhsczQzQVhWMkZCT3JXckwxUGRBeEFkd25lMlVFd3ZKTnVCajJkbGZ1U3Y2SE53clhJOWQweEtlUHlnLXBLb3JvWi14NGQxZHJyMXZ2bWhCTnN2eVhVbm9s?oc=5","date":"2026-03-31","type":"regulatory","source":"Fierce Pharma","summary":"FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen's Tavneos - Fierce Pharma","headline":"FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen's Tavneos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE4wLVRaUVp0S19wU1I2RUo5OEZDYjlkRDlKTGFlRnlPYWM0T3JQOXVlMEJPWGx0cnFCeXpNcEs3eVFpeko3NzRDcEtncXhnUldtNW1IaG52QjBZRVVjaVhKUEZCbGdyLVlJLTBVTEdMZzBVRkUwaFlPRFRrSQ?oc=5","date":"2026-02-05","type":"regulatory","source":"pharmaphorum","summary":"Amgen baulks at FDA request to withdraw Tavneos - pharmaphorum","headline":"Amgen baulks at FDA request to withdraw Tavneos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQYnpPZlpvSXZkSERkb2o0aWc2RHViZm5TU0x0OTFRZVhEd2hhUjB0OWhaVTdiRlI2VmtkUEVzaTg1aGhIM28yd2Z5bnlrWUg3c1RoT043TUtfdWdmYmY1Qk9pYlFKVzFER2M4VGhCRnZDYU1UUmR3cmhYUXpOcnI0ZA?oc=5","date":"2026-01-30","type":"regulatory","source":"pharmaphorum","summary":"EMA looks into 'data integrity' issue with Amgen's Tavneos - pharmaphorum","headline":"EMA looks into 'data integrity' issue with Amgen's Tavneos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQeTJQdkVkemJWZnpTZFBPNExoRDRaSFNKeHhZZkNvb2Q3TEtGWm51cnU3Wnl3MUVxUXcyWkdnUkE1b1pnd1E3cnJvaFJ2V1VIa0VucExOR0JMdXVtMEN2cXdrYU1nUGhBOV91cDhXNEdZZ3BlRWk5N2o4akZOdG1qMDZXY21rQzd4NHpHbVJzaUszUnd3SGVHcG5JbkFRaEJqN2hWd0tyc1NxSVJwY0ZTWU9pUjd6UjZTQUhFQW9XREdFU2VSb1BMN0NPNWV4ZVdQVlFPWXV6aU5NelJUQTBkUjh4dGQ?oc=5","date":"2025-08-16","type":"pipeline","source":"Neos Kosmos","summary":"From Marrickville’s shopfront to national leadership: Caroline Diamantis on the changing face of pharmacy - Neos Kosmos","headline":"From Marrickville’s shopfront to national leadership: Caroline Diamantis on the changing face of pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9RNkdMRmFnR2FFOWtQN2gyaXNYbndzOFlGQ3dsV2ZlY1BsN0ZfdVo2MVV4VDVBWkNybERTYjVSZi1hdVlkU0gwdFl0LUZ6V0FUOFJF?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"NEOS Stock Price, News & Analysis - Stock Titan","headline":"NEOS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5BQkR6bzdxZ1dmbHlrT0FJTDVLVXdpalN4X3lZam41VkJ5R3VKeVFOUEUzeTh2dElfWWtaSG83SGFRQVZqV0habnBwR2FFRm9iM2xta2dsbGo0SXRSUGlDWkdxOEhnVExOcXc?oc=5","date":"2023-12-09","type":"trial","source":"Neurology® Journals","summary":"Retrospective Pediatric Cohort Study Validates NEOS Score and Demonstrates Applicability in Children With Anti-NMDAR Encephalitis - Neurology® Journals","headline":"Retrospective Pediatric Cohort Study Validates NEOS Score and Demonstrates Applicability in Children With Anti-NMDAR Enc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVk93SEVjaXpUMFdSMWZCamxHTnc2eTMtSW0zanQxTzFNZTZtSVZRSDh1clNEY1lfRS05c0loSXZodkl6WUJLcUNHYmV4dFVOaFpYOHZXOFBPZnFfSzFfUEpyOGNhbmRRQi13LWFIdy15MTB5WDdtOVFSUjdHc2RBVXRjd0hBQ1dvVE1NV0JSSmVOS0VDc1FtYVh0WXZxQ193aVJrOVZGQ2lxaWstVWtwckZ6UW9HdVJLVWxBc3dLSEtpR0Y2Ynh3aGEzM3RNNm8wMlo2YWt1ckhoaExy?oc=5","date":"2021-03-22","type":"deal","source":"ACCESS Newswire","summary":"Aytu BioScience Announces Close of Merger with Neos Therapeutics - ACCESS Newswire","headline":"Aytu BioScience Announces Close of Merger with Neos Therapeutics","sentiment":"neutral"},{"date":"2021-03-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOd0J0Y3BnM0Z3NlgxTnYzV2tPY2NLb09Wc0lqYUpDT1hNd3NLZHY5anl3Wno4QmI2Ukdnc2J5SWN4MmJ4bjdRSGFHRWxIVVh6REcyUmZTM3NtQmpFN1VWYmhkOHlIREdzWTJvb25vSnZ4WE5yel9RUU1WeDdIc1oyY2pTTEJtQjdOM2Yxcm5lZGtwdkdBY3k1NmhLay05bzRhd1Jr0gGoAUFVX3lxTE1PTE5GRDVnb21RWkphVEVHZ1ZnM2tuOGppZjM5dWUzTGNyYm9CWXBKUFBVV0lLMDl4ZFFDdDBzQkpSYThnUGJDTC1lbko1bzdiQkpEUGZDS0s5MDlwbFNmQng3N1lIZUVoVU00ZzZ3S1FZLXUtREdzTm1TSk9WQ1ozWkVCdnpxN0xrNnMzYmxtN1EtdlRwRGVkbGtPOVhKUU5QVFRPQzdFeA?oc=5","date":"2020-01-03","type":"pipeline","source":"CBS News","summary":"Big Pharma companies raised prices on more than 400 drugs to start 2020 - CBS News","headline":"Big Pharma companies raised prices on more than 400 drugs to start 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdXdOSmpyTkp1SjllWExPcEcxOC1YSl95ZTE1WEMyb0dGdXpZd2NONE5SRnd2eUxTUzE3LW5TYXdTWE1aWE4zckNKemFHalU1V29iaDY5RnlBSHd1WkFsZ3hFQll5MVNTUFZJV016dTZRLXdqa1BuODdOX21ZQkQyWTc2a296MkVudzlORmRLd1dMd0dkb3NYanY3N0pJcndqRGc?oc=5","date":"2019-02-05","type":"pipeline","source":"dallasinnovates.com","summary":"DI People: Neiman Marcus, Pier 1, Crayon, Neos Therapeutics Make Exec Moves - dallasinnovates.com","headline":"DI People: Neiman Marcus, Pier 1, Crayon, Neos Therapeutics Make Exec Moves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdjdLYTBodHVqcDhhMk1mZllMZVkyMkZnbjMwVkhpdGc3OTJWNjVLM3FjWHFfUDVQRl8yT0ZtWDl3NFJaYjl2OVFLOXljYlRlaGtDdkV0bGRJRUQtcmZkOGdFNm9RRXdJRkNKMHVSNkttNGVxQVU1VGM2MkhrY3lETjRMYzlrNUVJdVJVS0c3eW5mLXZSLXpfWVNoOUxYYmlPSEt5dmE2NmhPWWhxWE9DSldtWUh6dThs?oc=5","date":"2018-10-29","type":"deal","source":"BioSpace","summary":"Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling) - BioSpace","headline":"Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOVHphUklkcC1iaVFiTzBSdllFN29pa2RVa05oa3RQRWdIUjBOaS1aLXNNTHVKeW5zVGRpck1PeTVCY19SNk9RQzdSS0x4bHdEWHEzLUI4MDFjY3NyenFCRm01MUliYk56YnU3c1lvSTRDX0IzY0l3dXhQeFlQUTV0OG1STGcxSGh6b3NOdXVXWXlhX3NlTGZFVm5fdm8zQ2ZMelE?oc=5","date":"2018-06-28","type":"pipeline","source":"Fierce Biotech","summary":"Neos poaches AgeneBio chief as CEO Vipin Garg abruptly resigns - Fierce Biotech","headline":"Neos poaches AgeneBio chief as CEO Vipin Garg abruptly resigns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxON0VmaU5Keks4a1ZzSFdVcXVxaEVxS2pjU3c3djNzVWk5RHpsbjkyTXM5MmVoRmF2NDhGeWsxQ2RNWnBYWTdNaENZUlhHbnlWQklCTU5LSmMwakRsOEZNNmY4WkFrWHFDZFFubld4Y1Mzb1hYNFRVYU1SYUJsaWZTN05Ja3M2bU84UFU5RmhtX1V5M0FqVEVoOXA2SmNNeWU4WlZrS1VJaDFKWDNwRUxSWkpJcnFHQTg?oc=5","date":"2017-06-20","type":"regulatory","source":"Fierce Pharma","summary":"Neos, facing criticism, wins approval for another easy-to-take pediatric ADHD medication - Fierce Pharma","headline":"Neos, facing criticism, wins approval for another easy-to-take pediatric ADHD medication","sentiment":"positive"}],"patents":[{"drugName":"Adzenys ER","drugSlug":"amphetamine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Cotempla","drugSlug":"methylphenidate","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":50000000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Shire","Novartis","Teva"],"therapeuticFocus":["CNS","ADHD"],"financials":{"source":"sec_edgar+yahoo","revenue":64649000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":64649000,"period":"2019-12-31"},{"value":16832000,"period":"2019-12-31"},{"value":17540000,"period":"2019-09-30"},{"value":15643000,"period":"2019-06-30"},{"value":14634000,"period":"2019-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8582000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-16902000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":90873000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}